A review with 402 references
Atherosclerosis is a complex cardiovascular disease driven by multiple factors, including aging, inflammation, oxidative stress, and plaque rupture. The progression of this disease is often covert, emphasizing the need for early biomarkers and effective intervention measures. In recent years, advancements in therapeutic strategies have highlighted the potential of targeting specific processes in atherosclerosis, such as plaque localization, macrophage activity, and key enzymes. Based on this, this review discusses the potential role of targeted drugs in the treatment of atherosclerosis.
Two CD-based drug delivery systems are cited:
- Simultaneous Rosiglitazone release and low-density lipoprotein removal by chondroitin sodium sulfate/cyclodextrin/poly (acrylic acid) composite adsorbents for atherosclerosis therapy [2]
- Macrophage Membrane-Encapsulated Dopamine-Modified Poly cyclodextrin multifunctional biomimetic nanoparticles for atherosclerosis therapy [3]
References:
Tu, L., Zou, Z., Yang, Y. et al. Targeted drug delivery systems for atherosclerosis. J Nanobiotechnol 23, 306 (2025). https://doi.org/10.1186/s12951-025-03384-0
[2] Xiao Y, Xu Y, Liu X, Chen L, Wang Q, Zhang P, et al. Biomacromolecules. 2024;25(5):3141–52. https://doi.org/10.1021/acs.biomac.4c00241
[3] Zhu L, Zhong Y, Yan M, et al. ACS Appl Mater Interfaces. 2024;16(25):32027–44. https://doi.org/10.1021/acsami.4c04431
Read also: